Facebook
X
LinkedIn
ForwardOctober 9, 2025: Prevention, Monitoring, and Management of Adverse Events Associated With BCMA-Directed Bispecific Antibodies in Multiple Myeloma Enduring
Welcome to the second session of our ECHO program!
Prevention, Monitoring, and Management of Adverse Events Associated With BCMA-Directed Bispecific Antibodies in Multiple Myeloma
Target Audience:
Oncologists, hematologists, PAs, NPs, nurses, nurse navigators, pharmacists and other healthcare professionals (HCPs) responsible for the care and treatment of people living with RRMM.
Please click on: Take Course the day of the session to access the zoom link.
Learning Objectives:
- Describe the diagnosis, risk factors, prevention and management of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS)
- Recognize infectious complications associated with BCMA-directed bispecific antibodies and implement strategies for their prevention.
- Establish and follow workflows and lines of communication for monitoring and managing BCMA BsAb treatment-related adverse events (TRAEs)
Grantor Acknowledgement
This activity is supported by educational grants from Pfizer Inc. and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Sara Scott, PharmD, BCOP
Oncology Clinical Pharmacy Specialist
Winship Cancer Institute
Emory Healthcare
Atlanta, GA
Sara Scott, PharmD, BCOP, is a board-certified clinical pharmacy specialist in multiple myeloma at Emory Winship Cancer Institute. She received a BS in biomedical engineering at the University of Utah. She completed her PharmD at The University of North Carolina at Chapel Hill. After school, she completed her PGY1 pharmacy residency at Vanderbilt University Medical Center in Nashville, Tennessee, and her PGY2 oncology pharmacy residency at The University of Kansas Health System in Kansas City, Kansas. She is an active member of Hematology/Oncology Pharmacy Association and the American Society for Transplantation and Cellular Therapy. Her professional interests include multiple myeloma, bone marrow transplant, and cellular therapy.
Dr. Sara Scott is a consultant for GlaxoSmithKline, J&J Innovative Medicine, Pfizer Inc., and Sanofi.
Disclosure Policy:
Boston University Chobanian & Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University Chobanian & Avedisian School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships that faculty, planners, authors, and anyone who may be in control of content have with ineligible companies have been mitigated.
Accreditation Statement
This activity is developed as a joint collaboration among Boston University Chobanian & Avedisian School of Medicine, Med-IQ, the AAPA, the Association of PAs in Oncology (APAO), and HealthTree Foundation.
In support of improving patient care, this activity has been planned and implemented by Boston University Chobanian & Avedisian School of Medicine and Med-IQ. Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Accreditation
Boston University Chobanian & Avedisian School of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine Maintenance of Certification (MOC) Part 2 Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By participating and claiming credit, you agree to BU sharing your information with ACCME PARS the data conduit to the ABIM.
Nurse Accreditation
Nursing Contact Hours: 1.0, of which 1.0 is eligible for pharmacology credit.
Pharmacist Accreditation
This activity is approved for 1.0 CPE credit.
UAN: JA0000185-9999-25-040-L01-P
Physician Associate Accreditation
Boston University Chobanian & Avedisian School of Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.
Available Credit
- 1.00 AAPA Category I CME
- 1.00 ABIM Medical Knowledge
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
Boston University Chobanian & Avedisian School of Medicine designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 ANCC
- 1.00 ANCC Pharmacology
- 1.00 Participation
Thank you for registering for our first session!
Once you have participated in the meeting, click on the link provided in the chat or in your calendar invite to come back here. Click on "Take Course" above to complete the evaluation and claim credit.
Please contact [email protected] with any questions of if you need assistance.